Physician profile
Randolph Eamonn Brown
NPI 1902127228
$2,850.46
in general payments reported to CMS, 2019-2025
21 companies · $310 in 2025
The $310 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2023: $695 · 2024: $1,596 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,964 · Travel and Lodging: $473 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,963.91 |
| Travel and Lodging | $472.50 |
| Education | $164.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,194.19 | 2024 | Optis |
| Janssen Pharmaceuticals, INC | $276.77 | 2023-2024 | Xarelto |
| Boston Scientific Corporation | $249.66 | 2024-2025 | Watchman Flx, Watchman |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $194.00 | 2019-2025 | Lifevest |
| Medtronic, INC. | $192.54 | 2023 | Onyx Frontier, Linq II |
| Chiesi USA, INC. | $116.38 | 2023 | Kengreal |
| Merck Sharp & Dohme LLC | $86.67 | 2023-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $70.12 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $64.51 | 2019-2024 | Farxiga |
| Abiomed | $61.47 | 2023-2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.20 | 2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $49.46 | 2019-2023 | Amvuttra |
| Pfizer INC. | $46.92 | 2023 | |
| Amgen INC. | $41.97 | 2019-2024 | Repatha |
| Esperion Therapeutics, INC. | $33.75 | 2025 | Nexletol |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $28.54 | 2024 | Arcalyst |
| Cardiva Medical, INC. | $20.33 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Kestra Medical Technology Services, INC. | $18.52 | 2024 | Assure Wcd |
| Philips North America LLC | $17.04 | 2025 | Mcot |
| Scpharmaceuticals INC. | $16.25 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $14.17 | 2025 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randolph Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.